Intranasal immunization with H5N1 vaccine plus Poly I:Poly C12U, a Toll-like receptor agonist, protects mice against homologous and heterologous virus challenge
Intranasal immunization with H5N1 vaccine plus Poly I:Poly C12U, a Toll-like receptor agonist, protects mice against homologous and heterologous virus challenge
复制标题
DOI：
10.1016/j.micinf.2007.06.007
复制
发表时间：
2007-09-01
影响因子：
5.8
通讯作者：
Hasegawa, Hideki
中科院分区：
文献类型：
--
作者：
Ichinohe, Takeshi;Kawaguchi, Akira;Hasegawa, Hideki
H5 N1禽流感病毒有可能引起新的大流行。由于很难预测哪种流感病毒株会导致大流行，因此生产具有交叉保护性免疫力的疫苗是有利的。据报道，接种粘多糖疫苗可通过诱导粘膜表面分泌伊加来诱导交叉保护性免疫。佐剂还可以增强完全保护性粘膜免疫的发展。在这里，我们发现一种新的粘膜佐剂，polyI：polyC（12）U（Ampligen（R）），一种Toll样受体3激动剂，在III期人体试验中被证明是安全的，是H5 N1流感疫苗接种的有效佐剂。鼻内施用具有Ampligen的候选流感疫苗导致伊加分泌，并且保护随后用同源A/Vietnam/1194/2004和异源A/HK/483/97和A/Indonesia/6/2005病毒攻击的小鼠。(C)2007年，Elsevier Masson SAS。All rights reserved.
The avian H5N1 influenza virus has the potential to cause a new pandemic. Since it is difficult to predict which strain of influenza will cause a pandemic, it is advantageous to produce vaccines that confer cross-protective immunity. Mucosal vaccine administration was reported to induce cross-protective immunity by inducing secretion of IgA at the mucosal surface. Adjuvants can also enhance the development of fully protective mucosal immunity. Here we show that a new mucosal adjuvant, polyI:polyC(12)U (Ampligen (R)), a Toll-like receptor 3 agonist proven to be safe in a Phase III human trial, is an effective adjuvant for H5N1 influenza vaccination. Intranasal administration of a candidate influenza vaccine with Ampligen resulted in secretion of IgA, and protected mice that were subsequently challenged with homologous A/Vietnam/1194/2004 and heterologous A/HK/483/97 and A/Indonesia/6/2005 virus. (C) 2007 Elsevier Masson SAS. All rights reserved.